- This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne -
- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ clinical trial in March 2025 -
- Over 30 million acne patients seek treatment in the U.S. each year, with topical products being first-line therapy -
Read More